×

Pharmaceutical compositions comprising human antibodies to PCSK9

  • US 9,682,013 B2
  • Filed: 01/27/2012
  • Issued: 06/20/2017
  • Est. Priority Date: 01/28/2011
  • Status: Active Grant
First Claim
Patent Images

1. A unit dosage form of a pharmaceutical composition for single administration comprising a fixed dose of, 75 mg, 150 mg, or 300 mg of an antibody or an antigen-binding fragment thereof which specifically binds human proprotein convertase subtilisin/kexin type 9 (hPCSK9) together with a pharmaceutically acceptable excipient or carrier in a hermetically sealed container, wherein the antibody or antigen-binding fragment thereof comprises the three heavy chain CDRs set forth in SEQ ID NOs:

  • 76, 78, and 80 and the three light chain CDRs set forth in SEQ ID NOs;

    84, 86, and 88.

View all claims
  • 3 Assignments
Timeline View
Assignment View
    ×
    ×